Presentation is loading. Please wait.

Presentation is loading. Please wait.

ONLINE SUPPLEMENTAL MATERIAL

Published byReiner Gehrig Modified over 6 years ago

Similar presentations

Presentation on theme: "ONLINE SUPPLEMENTAL MATERIAL"— Presentation transcript:

1 ONLINE SUPPLEMENTAL MATERIAL
Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy Supplemental Figure 1. Associations between the changes in LPL mass and those in LDL cholesterol (Group 1)…………………………… 2 3 4 5 6 7 8 9 10 11 12 13 Supplemental Figure 2. Associations between the changes in LPL mass and those in TG (Group 1)………………………………………………. Supplemental Figure 3. Associations between the changes in LPL mass and those in RLP cholesterol (Group 1)…………………………… Supplemental Figure 4. Associations between the changes in LPL mass and those in LDL cholesterol (Group 2)……………………………. Supplemental Figure 5. Associations between the changes in LPL mass and those in TG (Group 2)………………………………………………. Supplemental Figure 6. Associations between the changes in LPL mass and those in RLP cholesterol (Group 2)…………………………… Supplemental Figure 7. Associations between the changes in EL mass and those in LDL cholesterol (Group 1)…………………………….. Supplemental Figure 8. Associations between the changes in EL mass and those in TG (Group 1)………………………………………………… Supplemental Figure 9. Associations between the changes in EL mass and those in RLP cholesterol (Group 1)…………………………….. Supplemental Figure 10. Associations between the changes in EL mass and those in LDL cholesterol (Group 2)…………………………… Supplemental Figure 11. Associations between the changes in EL mass and those in TG (Group 2)………………………………………………. Supplemental Figure 12. Associations between the changes in EL mass and those in RLP cholesterol (Group 2)……………………………

2 Supplemental Figure 1. Associations between the changes in LPL mass and those in LDL cholesterol (Group 1) A B C Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in LDL cholesterol (%) Percent change in LDL cholesterol (%) Percent change in LDL cholesterol (%)

3 Supplemental Figure 2. Associations between the changes in LPL mass and those in TG (Group 1)
Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in TG (%) Percent change in TG (%) Percent change in TG (%)

4 Supplemental Figure 3. Associations between the changes in LPL mass and those in RLP cholesterol (Group 1) A B C Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in RLP cholesterol (%) Percent change in RLP cholesterol (%) Percent change in RLP cholesterol (%)

5 Supplemental Figure 4. Associations between the changes in LPL mass and those in LDL cholesterol (Group 2) A B C Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in LDL cholesterol (%) Percent change in LDL cholesterol (%) Percent change in LDL cholesterol (%)

6 Supplemental Figure 5. Associations between the changes in LPL mass and those in TG (Group 2)
Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in TG (%) Percent change in TG (%) Percent change in TG (%)

7 Supplemental Figure 6. Associations between the changes in LPL mass and those in RLP cholesterol (Group 2) A B C Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in LPL mass (%) Percent change in RLP cholesterol (%) Percent change in RLP cholesterol (%) Percent change in RLP cholesterol (%)

8 Supplemental Figure 7. Associations between the changes in EL mass and those in LDL cholesterol (Group 1) A B C Percent change in EL mass (%) Percent change in EL mass (%) Percent change in EL mass (%) Percent change in LDL cholesterol (%) Percent change in LDL cholesterol (%) Percent change in LDL cholesterol (%)

9 Supplemental Figure 8. Associations between the changes in EL mass and those in TG (Group 1)
Percent change in EL mass (%) Percent change in EL mass (%) Percent change in EL mass (%) Percent change in TG (%) Percent change in TG (%) Percent change in TG (%)

10 Supplemental Figure 9. Associations between the changes in EL mass and those in RLP cholesterol (Group 1) A B C Percent change in EL mass (%) Percent change in EL mass (%) Percent change in EL mass (%) Percent change in RLP cholesterol (%) Percent change in RLP cholesterol (%) Percent change in RLP cholesterol (%)

11 Supplemental Figure 10. Associations between the changes in EL mass and those in LDL cholesterol (Group 2) A B C Percent change in EL mass (%) Percent change in EL mass (%) Percent change in EL mass (%) Percent change in LDL cholesterol (%) Percent change in LDL cholesterol (%) Percent change in LDL cholesterol (%)

12 Supplemental Figure 11. Associations between the changes in EL mass and those in TG (Group 2)
Percent change in EL mass (%) Percent change in EL mass (%) Percent change in EL mass (%) Percent change in TG (%) Percent change in TG (%) Percent change in TG (%)

13 Supplemental Figure 12. Associations between the changes in EL mass and those in RLP cholesterol (Group 2) A B C Percent change in EL mass (%) Percent change in EL mass (%) Percent change in EL mass (%) Percent change in RLP cholesterol (%) Percent change in RLP cholesterol (%) Percent change in RLP cholesterol (%)

Download ppt "ONLINE SUPPLEMENTAL MATERIAL"

Similar presentations

Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
Lipoprotein Structure, Function, and Metabolism

Lipoprotein Structure, Function, and Metabolism
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
The Antihyperlipidemic Medications l Classifications of Lipoproteins – Chylomicrons l Formed in the mucosal cells of the gut l Protein coated dietary lipids.

The Antihyperlipidemic Medications l Classifications of Lipoproteins – Chylomicrons l Formed in the mucosal cells of the gut l Protein coated dietary lipids.
A) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by UC and RA TC difference (RA-UC) 50100150200250 -80 -60 -40 -20 0 20 40 60 80 Average TC by.

A) Average TC by UC and RA TC difference (RA-UC) Average TC by.
1 LIPID TRANSPORT Lipoproteins Lipids are transported in the blood as lipoproteins are soluble in water because the surface consists of polar lipids.

1 LIPID TRANSPORT Lipoproteins Lipids are transported in the blood as lipoproteins are soluble in water because the surface consists of polar lipids.
HYPERLIPIDEMIA  Coronary heart disease (CHD) is the cause of about half of all deaths. The incidence of CHD is correlated with elevated levels of low-density.

HYPERLIPIDEMIA  Coronary heart disease (CHD) is the cause of about half of all deaths. The incidence of CHD is correlated with elevated levels of low-density.
Copyright © 2016 McGraw-Hill Education. All rights reserved.

Copyright © 2016 McGraw-Hill Education. All rights reserved.
Lipids in the diet are hydrolyzed in the small intestine, and the resultant fatty acids and monoglycerides are repackaged with apoB-48 into TG-enriched.

Lipids in the diet are hydrolyzed in the small intestine, and the resultant fatty acids and monoglycerides are repackaged with apoB-48 into TG-enriched.
Cholesterol-Lowering Ability of a Phytostanol Softgel Supplement in Adults with Mild to Moderate Hypercholesterolemia Woodgate D et al. Lipids. 2006;41:127-32.

Cholesterol-Lowering Ability of a Phytostanol Softgel Supplement in Adults with Mild to Moderate Hypercholesterolemia Woodgate D et al. Lipids. 2006;41:
Cardiovascular Disease

Cardiovascular Disease
Supplemental Figure 1 A B C D E F

Supplemental Figure 1 A B C D E F
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
Arch Intern Med. 2004;164(7): doi: /archinte Figure Legend:

Arch Intern Med. 2004;164(7): doi: /archinte Figure Legend:
M.Sc. in Pharmacy/Clinical Laboratory Sciences

M.Sc. in Pharmacy/Clinical Laboratory Sciences
Copyright © 2017 American Academy of Pediatrics.

Copyright © 2017 American Academy of Pediatrics.
Cost-Sharing for Plans Offered in the Federal Marketplace for 2018

Cost-Sharing for Plans Offered in the Federal Marketplace for 2018
Formative Test.

Formative Test.
A novel approach to target fasting and post-prandial triglycerides

A novel approach to target fasting and post-prandial triglycerides
Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved.

Similar presentations

Ads by Google